Rafael Holdings, Inc. filings document regulatory disclosures for a biotechnology company with Class B common stock listed on the New York Stock Exchange. The company’s reports include Form 8-K earnings releases, Regulation FD disclosures, clinical and intellectual-property updates tied to Cyclo Therapeutics, and material-event reporting related to its pharmaceutical development activities.
Proxy and meeting filings describe board elections, auditor ratification, equity incentive plan matters, committee governance and shareholder voting results. Securities-related filings cover Rafael’s Class B common stock, warrants to purchase Class B common stock, warrant exchange matters connected to the Cyclo Therapeutics merger, and Form 25 listing and registration notices for the warrant class.
Rafael Holdings insider activity: Joshua M. Fine, Chief Operating Officer, reported transactions on 09/03/2025. He disposed of 9,380 shares of Class B common stock, which are held jointly with his wife. On the same date he was granted 24,558 stock options with an exercise price of $1.38 that expire on 09/02/2035. The options vest in two equal installments of 12,279 shares on 09/03/2026 and 09/03/2027, conditioned on continuous service. Following these transactions he beneficially owns 24,558 option shares and reduced Class B share holdings by 9,380 shares.
Joshua M. Fine, Chief Operations Officer of Rafael Holdings, Inc. (RFL), filed a Form 3 reporting ownership following an event dated 08/04/2025. He holds 9,380 Class B common shares (held jointly with his wife) and stock options totaling 137,881 shares from five grants exercisable 2021–2025 with exercise prices ranging from $1.00 to $21.16. The shares and options were received or converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025.
Form 3 highlights: Director N. Scott Fine has filed his initial beneficial-ownership report after the 14 Jul 2025 business-combination event between Rafael Holdings (RFL) and Cyclo Therapeutics. He directly owns 335,348 Class B shares, including 3,525 held jointly with his spouse. In addition, he holds derivative rights on 373,945 Class B shares via five option grants (strikes $1.90-$21.16, expiries 2031-2035) and three warrants (strikes $2.70-$184.10, expiries 2025-2027). All securities were exchanged from prior Cyclo awards. The filing signals meaningful insider equity alignment but also identifies potential future dilution should the options and warrants be exercised.
Rafael Holdings, Inc. (RFL) has filed a Form S-8 registration statement to cover 1,393,077 additional shares of Class B common stock for employee equity compensation. The filing registers (i) 774,375 shares related to the amended and restated 2021 Rafael Holdings Equity Incentive Plan and (ii) 618,702 shares issuable under the Cyclo Therapeutics 2021 Omnibus Equity Incentive Plan.
The Cyclo shares stem from the 25 March 2025 merger in which Cyclo Therapeutics became a wholly owned subsidiary; all outstanding Cyclo options were assumed by Rafael and converted into options for Rafael Class B stock on substantially similar terms. The S-8 ensures that awards granted or to be granted under both plans are properly registered, allowing the company to issue shares upon exercise or vesting without further SEC registration.
The filing includes customary incorporation by reference of Rafael’s most recent 10-K, subsequent 10-Qs, numerous 8-Ks detailing merger progress, and exhibits such as legal opinions and auditor consents. Standard Delaware indemnification provisions for directors and officers are reiterated. No new financial results, capital-raising activities, or changes to business strategy are disclosed; the document is strictly administrative and facilitates post-merger equity compensation.
Rafael Holdings (RFL) Form 4 filing – CFO David Polinsky reported a routine tax-withholding transaction on 06/21/2025. The company withheld 2,347 Class B common shares, valued at $1.595 per share, to cover statutory taxes triggered by the vesting of restricted stock units. The filing is coded “F,” confirming the shares were not sold in the open market but surrendered to the issuer. Following the transaction, the CFO continues to beneficially own 268,075 Class B shares, comprising 76,882 shares held outright, 69,943 vested restricted shares, and 121,250 unvested restricted shares that will vest in scheduled tranches through 01/13/2029. No new shares were acquired and no open-market sale was executed; the transaction has no direct cash impact and does not signal a change in insider sentiment. The filing maintains broad insider alignment, as the CFO retains a meaningful equity stake worth roughly $0.43 million at the reported price. Overall, the Form 4 appears administratively routine with negligible impact on the company’s capital structure or market perception.